TheEdgeResearch
Home / Stocks / SUVEN.NS

Suven Life Sciences Limited (SUVEN.NS)

NSE Healthcare Drug Manufacturers - Specialty & Generic
$342.35 ▲ +4.87%
Market Cap
$78.07B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
0.80
52-Wk Range
124.11-371
CEO
Venkateswarlu Jasti
Country
IN
Currency
INR

Suven Life Sciences Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Hyderabad, TS, IN. The stock last traded at $342.35, up 4.87% on the session, giving a market capitalisation of $78.07B. Its beta of 0.80 implies it has historically moved less than the broad market.

Company profile
Exchange
National Stock Exchange of India
Employees
141
IPO date
2003-10-24
Headquarters
Hyderabad, TS, IN
About Suven Life Sciences Limited

Suven Life Sciences Limited operates as a clinical-stage biopharmaceutical enterprise dedicated to the identification, progression, and commercialization of innovative therapeutic solutions. Its primary focus lies in addressing neurodegenerative conditions across key markets including India, the United States, Europe, and other international territories. The company's core activities revolve around the discovery and subsequent development of new chemical entities (NCEs) specifically targeting disorders of the central nervous system (CNS). Among its promising pipeline assets are SUVN-502, intended for Alzheimer's disease and associated neuropsychiatric manifestations; SUVN-G3031, a potent and selective inverse agonist of the histamine H3 receptor, aimed at sleep and cognitive impairments; and SUVN-911, a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist designed to alleviate depressive disorders. Further advancing its portfolio, Suven is also working on SUVN-D4010, a potent, selective, orally bioavailable, and brain-penetrant partial agonist of the 5-HT4 receptor for cognitive dysfunctions; SUVN-I6107, addressing cognitive issues and schizophrenia; SUVN-M8036 for various psychiatric ailments; and SUVN-D1044, targeting gastrointestinal conditions. Established in 1989, the company is based in Hyderabad, India. It adopted its current name, Suven Life Sciences Limited, in 2003, having previously operated as Suven Pharmaceuticals Pvt. Ltd. Jasti Property and Equity Holdings Private Limited holds a controlling interest in Suven Life Sciences Limited, making it a subsidiary.

Comparable companies

Suven Life Sciences Limited is most often compared with the following Healthcare names:

GUFICBIO.BOGUFICBIO.NSINNOVACAP.NSRPGLIFE.BORPGLIFE.NSSPARC.BOSPARC.NS
More research on SUVEN.NS
SUVEN.NS technical analysis SUVEN.NS TheEdge Score Compare against peers
Open full interactive analysis & DCF →